Michael Bezuhly

Dr. Michael Bezuhly

orcid

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 April 2015 in Fibrogenesis & Tissue Repair
Verified
Journal Article
Open access
PDF file
AMAmanda M Murphy
Amanda M Murphy
AWAlison L Wong
Alison L Wong
MBMichael Bezuhly
Michael Bezuhly
Over the last decade, it has become clear that the role of angiotensin II extends far beyond recognized renal and cardiovascular effects. The presence of an autologous renin-angiotensin system has been demonstrated in almost all tissues of the body. It is now known that angiotensin II acts both independently and in synergy with TGF-beta to induce fibrosis via the angiotensin type 1 receptor (AT1) in a multitude of tissues outside of the cardiovascular and renal systems, including pulmonary fibrosis, intra-abdominal fibrosis, and systemic sclerosis. Interestingly, recent studies have described a paradoxically regenerative effect of the angiotensin system via stimulation of the angiotensin type 2 receptor (AT2). Activation of AT2 has been shown to ameliorate fibrosis in animal models of skeletal muscle, gastrointestinal, and neurologic diseases. Clinical reports suggest a beneficial role for modulation of angiotensin II signaling in cutaneous scarring. This article reviews current knowledge on the role that angiotensin II plays in tissue fibrosis, as well as current and potential therapies targeting this system.

5 May 2014 in International Journal of Cancer
Verified
Journal Article
Open access
PDF file
SGSimon Gebremeskel
Simon Gebremeskel
TLTerry LeVatte
Terry LeVatte
RLRobert S. Liwski
Robert S. Liwski
BJBrent Johnston
Brent Johnston
MBMichael Bezuhly
Michael Bezuhly
Tumor cells use activated platelets to promote their proliferation and metastatic potential. Because platelet activation is largely mediated through ADP engagement of purinergic P2Y12 receptors on platelets, we investigated the potential of the reversible P2Y12 inhibitor ticagrelor, a clinical agent used in the prevention of cardiovascular and cerebrovascular events, to inhibit tumor adhesion and metastasis. In B16-F10 melanoma intravenous and intrasplenic metastasis models, mice treated with a clinical dose of ticagrelor (10 mg/kg) exhibited marked reductions in lung (84%) and liver (86%) metastases. Furthermore, ticagrelor treatment improved survival compared to saline-treated animals. A similar effect was observed in a 4T1 breast cancer model, with reductions in lung (55%) and bone marrow (87%) metastases following ticagrelor treatment. In vitro, B16-F10 cells exhibited decreased interaction with platelets from ticagrelor-treated mice compared to saline-treated mice, an effect similar to that observed with blockade of glycoprotein IIbIIIa. Similarly, B16-F10 cells co-incubated with platelets from ticagrelor-treated mice exhibited reduced adhesion to endothelial monolayers compared to those co-incubated with platelets from saline-treated animals, an effect also observed in vivo. Interestingly, pretreatment of endothelial monolayers with ticagrelor did not result in reduced tumor cell adhesion. These findings support a role for P2Y12-mediated platelet activation in promoting metastases, and provide proof-of-concept for the clinical use of ticagrelor in the prevention of tumor metastasis.

11 January 2018 in Clinical & Experimental Metastasis
Verified
Journal Article
Closed access
PDF file
AGAlison J. Gareau
Alison J. Gareau
CBColin Brien
Colin Brien
SGSimon Gebremeskel
Simon Gebremeskel
RLRobert S. Liwski
Robert S. Liwski
BJBrent Johnston
Brent Johnston
MBMichael Bezuhly
Michael Bezuhly

5 October 2009 in Cancer
Verified
Journal Article
Closed access
PDF file
MBMichael Bezuhly
Michael Bezuhly
CTClaire Temple
Claire Temple
LSLeif J. Sigurdson
Leif J. Sigurdson
RDRoger B. Davis
Roger B. Davis
GFGordon Flowerdew
Gordon Flowerdew
ECE. Francis Cook
E. Francis Cook

1 January 2014 in Journal of Plastic, Reconstructive & Aesthetic Surgery
Verified
Journal Article
Closed access
ABA. Bishop
A. Bishop
PHP. Hong
P. Hong
MBMichael Bezuhly
Michael Bezuhly

1 August 2020 in Plastic and Reconstructive Surgery
Verified
Journal Article
Closed access
NJNadim Joukhadar
Nadim Joukhadar
DMDaniel F.R.C.S.C. McKee
Daniel F.R.C.S.C. McKee
LCLouise F.R.C.S.C. Caouette-Laberge
Louise F.R.C.S.C. Caouette-Laberge
MBMichael Bezuhly
Michael Bezuhly
Learning Objectives: After studying this article, the participant should be able to: 1. Describe normal ear anatomy and development, and evaluate the patient’s ears for differences in shape, size, prominence, and symmetry. 2. Identify common congenital ear deformities, including prominent ear, macrotia, Stahl ear, cryptotia, constricted ear, and lobule anomalies. 3. Describe both early nonoperative management and operative techniques for correction of these ear deformities. 4. Be aware of advantages and disadvantages of common and emerging techniques for correction of pediatric ear deformities. Summary: Whereas severe ear malformations such as microtia/anotia are rare, other ear deformities, such as prominent ear, Stahl ear, and cryptotia, are common. Although these ear deformities result in minimal physiologic morbidity, their psychological and cosmetic impact can be significant. Identifying these common deformities and understanding how they differ from normal ear anatomy is critical to their management. In cases where a deformity is identified in neonatal life, ear molding may obviate the need for surgery. Although various surgical techniques have been described for correction of common ear deformities, the surgeon should follow a careful stepwise approach to address the auricular deformity or deformities present. By using such an approach, complications may be minimized and predictable aesthetic outcomes achieved.